GENETIC INNOVATIONS IN AGRICULTURE IN INDIA

Why In News?

Former Principal Scientific Adviser to the Government of India highlighted the deployment of next-generation genetic tools—specifically CRISPR-Cas genome editing and synthetic apomixis—to safeguard India’s staple food crops against severe climate stress.

What Are Genetic Innovations In Indian Agriculture?

Definition: Genetic innovations in agriculture involve the deployment of molecular biology tools—primarily CRISPR-Cas genome editing (SDN-1 and SDN-2 categories) and synthetic apomixis (asexual seed propagation)—to alter native plant genomes without introducing foreign, transgenic DNA.

Site-Directed Nuclease (SDN) Framework: Regulatory architecture classifies targeted genome modifications under SDN-1 (small insertions/deletions via non-homologous end joining without donor DNA), SDN-2 (targeted template-mediated edits altering few base pairs), and SDN-3 (transgenic insertions of foreign genes regulated under the Environment (Protection) Act, 1986).

Synthetic Apomixis Mechanism: Apomixis induces asexual reproduction through seeds by bypassing female meiosis and fertilization, generating clonal embryos that fix and retain heterosis (hybrid vigor) across infinite planting generations.

Clean Molecular Footprint: Modern Indian gene-edited crops possess non-transgenic status because researchers breed out the cellular gene-editing machinery (Cas9 protein and guide RNA) during terminal seed cycles, matching traits achievable through natural mutagenesis.

What Is The Status Of Staples And Seeds In India?

Cereal Dominance: Rice and wheat continue to occupy more than 50% of India's total farmland. 

• Rice production sits at an all-time high of 150 million tonnes (led by West Bengal, Uttar Pradesh, and Telangana), while wheat production is steady at 118 million tonnes, heavily anchored by Uttar Pradesh, Madhya Pradesh, and Punjab.  

Rise of Horticulture: In a historic shift, horticulture production (362+ million metric tons) has surpassed traditional food grain output, driven by massive surges in vegetables and fruits.  

Packaged Staples Boom: On the consumer side, there is a migration from buying loose, unbranded commodities to packaged, branded staples. Led by major FMCG players like ITC (Aashirvaad), value-added and branded grains command higher retail margins and dominate urban retail shelf space.  

Nutrition: Driven by government procurement pushes and global health trends, India leads the world in millet production (18.59 million tonnes, led by Rajasthan). Meanwhile, oilseeds (led by Rajasthan and Gujarat) hit a record 43 million tonnes, though India remains reliant on vegetable oil imports. 

Seeds Market

The Indian seed industry is valued at approximately $4 billion to $5 billion, with projections to scale its global market footprint from 1% to 10% by 2035.  

Key Technology & Policy Drivers

• CRISPR Revolution: India becoming the first country globally to approve and distribute field-grown CRISPR-edited rice lines (SDN-1 and SDN-2 categories) to farmers. Innovations like Pusa DST Rice-1 allow crops to survive coastal salinity stress, while DRR Dhan-100 shortens maturity cycles to save groundwater. 

• Climate Resilience Over Yield: The central government introduced 184 new crop varieties tailored for extreme climate tolerance—such as flood-tolerant rice and heat-resistant wheat—to offset unpredictable monsoon patterns. 

• Regulatory Overhauls: The Draft Seeds Bill / Seed Act enforces strict commercial seed quality standards, QR-based digital traceability, and anti-counterfeit measures to protect farmers while expressly protecting the traditional right of smallholders to save and exchange unbranded seed.  

• Digital Agriculture: Under the Bharat-VISTAAR and AgriStack initiatives, the government has mapped over 28 crore agricultural plots using digital crop surveys, linking farmer IDs directly to precision climate advisories and seed distribution networks. 

What Structural Challenges Inhibit Genetic Innovations In India?

Stagnant Gross Research Expenditure: India’s Gross Expenditure on Research and Development (GERD) consistently hovers around 0.64% to 0.7% of its GDP, drastically lagging behind global peers like the U.S. (3.5%) or South Korea (4.8%). The Department of Biotechnology (DBT) faces restrictive budgetary limits relative to its economic growth targets.

Late-Stage Capital Deficit: While early-stage innovation is supported by public entities like the Biotechnology Industry Research Assistance Council (BIRAC), there is an extreme scarcity of domestic Series B and Series C venture capital. Startups regularly hit a financial dead-end during capital-intensive clinical trials or multi-location field validation.  

Market-Sector Imbalances: The Bio-Industrial sector dwarfs Bio-Agri and Bio-Pharma in terms of private commercial investment, leaving high-impact human therapeutics and staple crop genetics disproportionately reliant on underfunded public laboratories.  

Lack of End-to-End Clusters: Although India features dozens of biotech incubators, very few offer localized, plug-and-play pilot scale purification, fill-and-finish suites, or embedded regulatory affairs counseling. Innovators are forced to duplicate processes across separate cities, driving up overhead costs.  

Supply Chain Vulnerability: India relies heavily on foreign providers for basic scientific inputs—from high-grade reagents and specialized laboratory equipment to indigenous gene-synthesis pipelines. Delays in custom DNA/RNA synthesis shipping from overseas regularly paralyze research timelines.  

Asymmetric Trade Regimes: Divergent international standards mean Indian gene-edited outputs face non-tariff rejections in major export destinations (such as the EU) that maintain rigid precautionary testing or strict public registers, disincentivizing private companies from backing domestic crop innovations.

Overlapping Bureaucracy: Developing novel human biopharmaceuticals requires navigation through a fragmented multi-agency web—including the DBT, the Indian Council of Medical Research (ICMR), and the Central Drugs Standard Control Organisation (CDSCO)—slowing down adaptive clinical trial approvals.  

Way Forward 

Embrace Genome Editing (CRISPR & SDN-1/SDN-2): Expand the development and deployment of genome-edited varieties—such as Pusa DST Rice-1 and DRR Dhan-100 (Kamala)—which enhance yields and climate resilience without introducing foreign DNA.  

Scale Apomixis and Self-Cloning Technology: Invest in research like hybrid-vigor preservation via apomixis, allowing smallholder farmers to replant high-yielding hybrid seeds across multiple seasons without recurring commercial seed costs. 

Revitalize Fundamental Research in Plant Sciences: Reverse the "brain drain" of biology students moving exclusively into biomedical fields by updating university curricula and re-attracting talent to plant genetics, physiology, and host-pathogen interactions.  

Integrate National Genetic Resources: Strengthen pre-breeding programs and coordinate the ICAR-National Bureau of Plant Genetic Resources to systematically catalog, conserve, and utilize germplasm from the National Genebank.  

Clear Regulatory Bottlenecks: Establish a transparent, science-based national biosafety policy to bridge the gap between laboratory success and commercial field deployment for climate-resilient and biofortified crops.  

Conclusion

Expanding public investments in functional genomics and guaranteeing open-access seed distribution will fortify national food sovereignty while protecting smallholder economic viability.

Source: THEHINDU